About
Trastuzumab is a recombinant humanized monoclonal antibody specifically designed to target the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a growth-promoting protein found on the surface of some cancer cells, particularly in certain aggressive types of breast and gastric cancers. By binding to HER2, trastuzumab effectively blocks its signaling pathways, inhibits cancer cell proliferation, and triggers the immune system to destroy HER2-overexpressing cancer cells through mechanisms like antibody-dependent cell-mediated cytotoxicity. This highly targeted approach helps to significantly slow tumor growth, reduce the risk of recurrence, and improve patient outcomes, making it a cornerstone therapy for HER2-positive malignancies. It is administered intravenously as part of a comprehensive treatment regimen.
Uses
- Treatment of HER2-positive metastatic breast cancer.
- Adjuvant treatment of HER2-positive early breast cancer.
- Management of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
- Used in combination with various chemotherapy regimens.
Directions For Use
Administer intravenously under the supervision of an oncologist. Dosage and frequency are determined by body weight or fixed dose, and the specific cancer indication.
Benefits
- Specifically targets HER2-positive cancer cells.
- Significantly improves disease-free and overall survival.
- Reduces the risk of cancer recurrence.
- Effective in both early and advanced stages of HER2-positive cancers.
- Can be integrated into comprehensive treatment plans.
- Offers a targeted therapy with a well-defined mechanism.
Side Effects
- Cardiotoxicity (e.g., congestive heart failure)
- Infusion-related reactions (fever, chills, headache)
- Diarrhea
- Fatigue
- Nausea and vomiting
- Rash
- Abdominal pain
- Myalgia
- Cough
- Dyspnea
- Peripheral edema
- Anemia
Safety Measures
- Alcohol - No specific direct interaction with alcohol, but it's generally advisable to limit or avoid alcohol during cancer treatment to manage overall health and potential side effects.
- Pregnancy - Contraindicated in pregnancy due to potential for fetal harm, including oligohydramnios and fetal renal impairment. Effective contraception is required.
- Breastfeeding - Breastfeeding is not recommended during trastuzumab treatment and for a period after, due to the potential for serious adverse reactions in the infant.
- Liver - No specific dose adjustment is generally required for liver impairment, but caution is advised.
- Kidney - No specific dose adjustment is generally required for kidney impairment, but caution is advised.
- Lung - Rare but serious pulmonary toxicity, including interstitial pneumonitis and acute respiratory distress syndrome, has been reported. Monitor for respiratory symptoms.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!